|Articles|November 3, 2014
So Who’s in Charge of Medicines in Brussels?
So now we know who is to do what on health issues in the new European Commission. Or do we?
Advertisement
So now we know who is to do what on health issues in the new European Commission. Or do we?
The furor that the new boss of the commission, Jean-Claude Juncker, unleashed with the plans for his new team, weeks before it took office, is still reverberating around Brussels. Peter O’ Donnell reports on the fallout in
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns
2
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
3
GSK Enters $745 Million Worldwide Exclusive License Agreement with Empirico for Clinical-Stage First-In-Class Oligonucleotide Candidate
4
Novartis Enters $12 Billion Definitive Merger Agreement to Acquire Avidity Biosciences
5
